

FIG. 1A




FIG. 1B




FIG. 2




FIG. 3A





FIG. 3B



4/36


FIG. 4

FIG. 5A





FIG. 5B



7/36



FIG. 5C**FIG. 6A**

FIG. 6B




FIG. 7A





FIG. 7B



10/36

FIG. 8A




FIG. 8B





FIG. 8C









FIG. 10A



13/36



FIG. 10B

FIG. 11



Protein	V2 #	ka (1 /Ms)	kd (1 /s)	KD (kd/ka, M)	V2.3/V2.2 ka	V2.3/V2.2 kd	V2.3/V2.2 KD
Anti-ANG2 HL	V2.2	1.15E+06	1.68E-03	1.46 nM	5.6	91.1	16.3
Anti-ANG2 LH	V2.3	6.44E+06	1.53E-01	23.8 nM			

FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16A





FIG. 16B



20/36

FIG. 17A




FIG. 17B




FIG. 18A





FIG. 18B



22/36


FIG. 19A

FIG. 19B




FIG. 19C




FIG. 20




FIG. 21A




FIG. 21B







FIG. 21C





27/36


FIG. 22C

FIG. 23







FIG. 24






31/36

FIG. 26



TREATMENT	CNV GRADE	DAY 56		DAY 70		DAY 84	
		LESION COUNT	INCIDENCE	LESION COUNT	INCIDENCE	LESION COUNT	INCIDENCE
VEHICLE	IV	10	11.9%	6	7.1%	6	7.1%
	III	16	19.0%	16	19.0%	13	15.5%
	II	56	66.7%	62	73.8%	65	77.4%
	I	2	2.4%	0	0%	0	0%
	Total	84	100%	84	100%	84	100%
CAG-AFLB 1X10 ¹² vg	IV	10	11.9%	6	7.1%	6	7.1%
	III	17	20.2%	12	19.0%	13	15.5%
	II	63	75.0%	72	85.7%	71	84.5%
	I	3	3.6%	0	0%	0	0%
	Total	84	100%	84	100%	84	100%
CAG-AFLB- VEGFC-RNAi 1X10 ¹² vg	IV	10	11.9%	6	7.1%	6	7.1%
	III	11	13.6%	8	9.9%	12	14.8%
	II	69	85.2%	73	90.1%	69	85.2%
	I	1	1.2%	0	0%	0	0%
	Total	84	100%	84	100%	84	100%
CAG-AFLB- VEGFC-RNAi 3X10 ¹¹ vg	IV	10	11.9%	6	7.1%	6	7.1%
	III	16	19.0%	16	19.0%	13	15.5%
	II	56	66.7%	62	73.8%	65	77.4%
	I	2	2.4%	0	0%	0	0%
	Total	84	100%	84	100%	84	100%
CAG-AFLB- VEGFC-RNAi	IV	0	0%	0	0%	0	0%
	III	16	19.0%	13	15.5%	14	16.7%
	II	67	79.8%	70	83.3%	70	83.3%
	I	1	1.2%	1	1.2%	0	0%
	Total	84	100%	84	100%	84	100%

FIG. 27



33/36


FIG. 28

FIG. 29




FIG. 30




FIG. 31

